Susan M Meffert1, Thomas C Neylan1,2, Charles E McCulloch3, Kelly Blum1, Craig R Cohen4, Elizabeth A Bukusi5,6,7, Helen Verdeli8, John C Markowitz9, James G Kahn10, David Bukusi11, Harsha Thirumurthy12, Grace Rota13, Ray Rota13, Grace Oketch13, Elizabeth Opiyo13, Linnet Ongeri14. 1. Department of Psychiatry, University of California, San Francisco (UCSF), San Francisco, California, United States of America. 2. Mental Health Service, San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America. 3. Department of Epidemiology & Biostatistics, UCSF, San Francisco, California, United States of America. 4. Department of Obstetrics, Gynecology & Reproductive Sciences, Bixby Center for Global Reproductive Health, UCSF, San Francisco, California, United States of America. 5. Departments of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America. 6. Center for Microbiology Research, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya. 7. Department of Obstetrics and Gynecology, Aga Khan University, Nairobi, Kenya. 8. Teachers College, Columbia University, New York, New York, United States of America. 9. Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, United States of America. 10. Philip R. Lee Institute for Health Policy Studies, Global Health Sciences, and Global Health Economics Consortium, UCSF, San Francisco, California, United States of America. 11. Department of Psychiatry, Kenyatta National Hospital, University of Nairobi, Nairobi, Kenya. 12. Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America. 13. University of Nairobi, Nairobi, Kenya. 14. KEMRI, Nairobi, Kenya.
Abstract
BACKGROUND:HIV-positive women suffer a high burden of mental disorders due in part to gender-based violence (GBV). Comorbid depression and posttraumatic stress disorder (PTSD) are typical psychiatric consequences of GBV. Despite attention to the HIV-GBV syndemic, few HIV clinics offer formal mental healthcare. This problem is acute in sub-Saharan Africa, where the world's majority of HIV-positive women live and prevalence of GBV is high. METHODS AND FINDINGS: We conducted a randomized controlled trial at an HIV clinic in Kisumu, Kenya. GBV-affected HIV-positive women with both major depressive disorder (MDD) and PTSD were randomized to 12 sessions of interpersonal psychotherapy (IPT) plus treatment as usual (TAU) or Wait List+TAU. Nonspecialists were trained to deliver IPT inside the clinic. After 3 months, participants were reassessed, and those assigned to Wait List+TAU were given IPT. The primary outcomes were diagnosis of MDD and PTSD (Mini International Neuropsychiatric Interview) at 3 months. Secondary outcomes included symptom measures of depression and PTSD, intimate partner violence (IPV), and disability. A total of 256 participants enrolled between May 2015 and July 2016. At baseline, the mean age of the women in this study was 37 years; 61% reported physical IPV in the past week; 91% reported 2 or more lifetime traumatic events and monthly income was 18USD. Multilevel mixed-effects logistic regression showed that participants randomized to IPT+TAU had lower odds of MDD (odds ratio [OR] 0.26, 95% CI [0.11 to 0.60], p = 0.002) and lower odds of PTSD (OR 0.35, [0.14 to 0.86], p = 0.02) than controls. IPT+TAU participants had lower odds of MDD-PTSD comorbidity than controls (OR 0.36, 95% CI [0.15 to 0.90], p = 0.03). Linear mixed models were used to assess secondary outcomes: IPT+TAU participants had reduced disability (-6.9 [-12.2, -1.5], p = 0.01), and nonsignificantly reduced work absenteeism (-3.35 [-6.83, 0.14], p = 0.06); partnered IPT+TAU participants had a reduction of IPV (-2.79 [-5.42, -0.16], p = 0.04). Gains were maintained across 6-month follow-up. Treatment group differences were observed only at month 3, the time point at which the groups differed in IPT status (before cross over). Study limitations included 35% attrition inclusive of follow-up assessments, generalizability to populations not in HIV care, and data not collected on TAU resources accessed. CONCLUSIONS:IPT for MDD and PTSD delivered by nonspecialists in the context of HIV care yielded significant improvements in HIV-positive women's mental health, functioning, and GBV (IPV) exposure, compared to controls. TRIAL REGISTRATION: Clinical Trials Identifier NCT02320799.
RCT Entities:
BACKGROUND: HIV-positive women suffer a high burden of mental disorders due in part to gender-based violence (GBV). Comorbid depression and posttraumatic stress disorder (PTSD) are typical psychiatric consequences of GBV. Despite attention to the HIV-GBV syndemic, few HIV clinics offer formal mental healthcare. This problem is acute in sub-Saharan Africa, where the world's majority of HIV-positive women live and prevalence of GBV is high. METHODS AND FINDINGS: We conducted a randomized controlled trial at an HIV clinic in Kisumu, Kenya. GBV-affected HIV-positive women with both major depressive disorder (MDD) and PTSD were randomized to 12 sessions of interpersonal psychotherapy (IPT) plus treatment as usual (TAU) or Wait List+TAU. Nonspecialists were trained to deliver IPT inside the clinic. After 3 months, participants were reassessed, and those assigned to Wait List+TAU were given IPT. The primary outcomes were diagnosis of MDD and PTSD (Mini International Neuropsychiatric Interview) at 3 months. Secondary outcomes included symptom measures of depression and PTSD, intimate partner violence (IPV), and disability. A total of 256 participants enrolled between May 2015 and July 2016. At baseline, the mean age of the women in this study was 37 years; 61% reported physical IPV in the past week; 91% reported 2 or more lifetime traumatic events and monthly income was 18USD. Multilevel mixed-effects logistic regression showed that participants randomized to IPT+TAU had lower odds of MDD (odds ratio [OR] 0.26, 95% CI [0.11 to 0.60], p = 0.002) and lower odds of PTSD (OR 0.35, [0.14 to 0.86], p = 0.02) than controls. IPT+TAUparticipants had lower odds of MDD-PTSD comorbidity than controls (OR 0.36, 95% CI [0.15 to 0.90], p = 0.03). Linear mixed models were used to assess secondary outcomes: IPT+TAUparticipants had reduced disability (-6.9 [-12.2, -1.5], p = 0.01), and nonsignificantly reduced work absenteeism (-3.35 [-6.83, 0.14], p = 0.06); partnered IPT+TAUparticipants had a reduction of IPV (-2.79 [-5.42, -0.16], p = 0.04). Gains were maintained across 6-month follow-up. Treatment group differences were observed only at month 3, the time point at which the groups differed in IPT status (before cross over). Study limitations included 35% attrition inclusive of follow-up assessments, generalizability to populations not in HIV care, and data not collected on TAU resources accessed. CONCLUSIONS: IPT for MDD and PTSD delivered by nonspecialists in the context of HIV care yielded significant improvements in HIV-positive women's mental health, functioning, and GBV (IPV) exposure, compared to controls. TRIAL REGISTRATION: Clinical Trials Identifier NCT02320799.
Authors: David C Mohr; Bonnie Spring; Kenneth E Freedland; Victoria Beckner; Patricia Arean; Steven D Hollon; Judith Ockene; Robert Kaplan Journal: Psychother Psychosom Date: 2009-07-11 Impact factor: 17.659
Authors: Daisy R Singla; Brandon A Kohrt; Laura K Murray; Arpita Anand; Bruce F Chorpita; Vikram Patel Journal: Annu Rev Clin Psychol Date: 2017-05-08 Impact factor: 18.561
Authors: Janine Archer; Peter Bower; Simon Gilbody; Karina Lovell; David Richards; Linda Gask; Chris Dickens; Peter Coventry Journal: Cochrane Database Syst Rev Date: 2012-10-17
Authors: Mia Du Zeying; Thulani Ashcroft; Durga Kulkarni; Vilas Sawrikar; Caroline A Jackson Journal: J Glob Health Date: 2022-06-11 Impact factor: 7.664
Authors: Susan M Meffert; Collene Lawhorn; Linnet Ongeri; Elizabeth Bukusi; Holly R Campbell; Eric Goosby; Stefano M Bertozzi; Simon Njuguna Kahonge Journal: Glob Ment Health (Camb) Date: 2021-11-11
Authors: K J Sikkema; S Rabie; A King; M H Watt; M I Mulawa; L S Andersen; P A Wilson; A Marais; E Ndwandwa; S Majokweni; C Orrell; J A Joska Journal: Trials Date: 2022-08-18 Impact factor: 2.728
Authors: M Bridget Spelke; Ravi Paul; Bryan S Blette; Samantha Meltzer-Brody; Crystal E Schiller; J M Ncheka; Margaret P Kasaro; Joan T Price; Jeffrey S A Stringer; Elizabeth M Stringer Journal: J Int AIDS Soc Date: 2022-07 Impact factor: 6.707